Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Licenses Xenomics' IP for Leukemia-linked Gene

NEW YORK (GenomeWeb News) - Xenomics said today it has granted a co-exclusive license to Asuragen to use the NPM1 gene to develop diagnostic products for acute myeloid leukemia patients.
 
Under the sub-license agreement, Asuragen will have access to use the nucleophosmin gene, or NPM1, toward developing tests to diagnose, stratify, and monitor AML patients.
 
Xenomics holds exclusive rights to a recent discovery at the University of Perugia that has shown that many AML patients have mutations in that gene.
 
Such a test could help doctors select patients who are most likely to benefit from intensive chemotherapy, "while sparing others with a low probability of benefit from the toxic treatment," the company said.  

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.